Ribo Announces Phase 2 Clinical Trial Submission To EMA, Further Advancing Sirna Therapeutics In Thromboembolic Disease

(MENAFN - PR Newswire) SUZHOU, China and MO–LNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938) and Ribocure Pharmaceuticals (together "Ribo") announce the ...